{"id":53538,"date":"2023-02-01T18:03:27","date_gmt":"2023-02-01T17:03:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/"},"modified":"2023-02-01T18:03:27","modified_gmt":"2023-02-01T17:03:27","slug":"kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/","title":{"rendered":"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer"},"content":{"rendered":"
\n

\nPioneering cell therapy leader will direct Stemson\u2019s efforts to develop the first iPSC-derived cell therapy to treat hair loss<\/i>\n<\/p>\n

SAN DIEGO–(BUSINESS WIRE)–#stemson<\/a>—Stemson Therapeutics<\/a>, a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Kevin D\u2019Amour, a veteran cell therapy development expert, has joined Stemson as Chief Scientific Officer. Kevin brings two decades of stem cell-derived cell therapy development experience to the Stemson team.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are delighted to have Kevin join our team and bring his extensive experience in cell therapy development,\u201d said Geoff Hamilton, Stemson\u2019s Cofounder and Chief Executive Officer. \u201cHe is a pioneer in the field of differentiating stem cells to yield therapeutically relevant cells to treat degenerative diseases. His addition will complement and bolster our world class R&D organization and accelerate our mission to develop a breakthrough hair follicle regeneration cell therapy.\u201d\n<\/p>\n

\n\u201cI am excited and honored to join the Stemson team,\u201d said Kevin. \u201cStemson\u2019s approach to replace lost hair with de novo follicles has tremendous promise and has the potential to bring true hair replacement therapy to a very large patient population. The company has progressed significantly in the past year and I look forward to working with Stemson\u2019s talented team to rapidly advance the program toward the clinic.\u201d\n<\/p>\n

\nKevin D\u2019Amour, PhD, was at ViaCyte from 2002 until 2021 and served as the company\u2019s Chief Scientific Officer from 2011 \u2013 2021. At ViaCyte, he led the development of the first stem cell-derived cell therapies designed to replace pancreatic beta cells for the treatment of type 1 diabetes. Under Kevin\u2019s leadership, ViaCyte took three cell therapy products into the clinic. ViaCyte was acquired by Vertex in 2022. After his time at ViaCyte, Kevin was Chief Scientific Officer of Brooklyn ImmunoTherapeutics where he focused on developing cell therapies using mRNA-based cell engineering technology. Kevin is co-author of high-profile publications in renowned scientific journals and an inventor on over 100 patents in the field of stem cells, cell engineering, and cell therapy.\n<\/p>\n

\nKevin earned his PhD in Biology from the University of California, San Diego.\n<\/p>\n

\nAbout Stemson Therapeutics<\/span><\/b>\n<\/p>\n

\nStemson Therapeutics is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cells. Based on the breakthrough innovation by Stemson Therapeutics co-founder, Dr. Alexey Terskikh, Stemson uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss. The iPSC-derived cells are used to grow de novo hair follicles, offering a new supply of hair to treat people suffering from various forms of Alopecia<\/a>. Today, there are no available treatments capable of growing new hair follicles. Stemson\u2019s world class team of scientists, advisors and collaborators are passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition. Stemson Therapeutics is headquartered in San Diego, CA. For more information, please visit www.stemson.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nStemson Therapeutics
\n
Amy Caterina
\n
amy@stemsontx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Pioneering cell therapy leader will direct Stemson\u2019s efforts to develop the first iPSC-derived cell therapy to treat hair loss SAN DIEGO–(BUSINESS WIRE)–#stemson—Stemson Therapeutics, a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Kevin D\u2019Amour, a veteran cell therapy development expert, has joined Stemson as Chief Scientific … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-53538","format-standard","category-industry"],"yoast_head":"\nKevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Pioneering cell therapy leader will direct Stemson\u2019s efforts to develop the first iPSC-derived cell therapy to treat hair loss SAN DIEGO–(BUSINESS WIRE)–#stemson—Stemson Therapeutics, a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Kevin D\u2019Amour, a veteran cell therapy development expert, has joined Stemson as Chief Scientific ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T17:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230201005196\/en\/1702775\/21\/D%27Amour_Professional_Headshot_%28002%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer\",\"datePublished\":\"2023-02-01T17:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/\"},\"wordCount\":526,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005196\\\/en\\\/1702775\\\/21\\\/D%27Amour_Professional_Headshot_%28002%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/\",\"name\":\"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005196\\\/en\\\/1702775\\\/21\\\/D%27Amour_Professional_Headshot_%28002%29.jpg\",\"datePublished\":\"2023-02-01T17:03:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005196\\\/en\\\/1702775\\\/21\\\/D%27Amour_Professional_Headshot_%28002%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005196\\\/en\\\/1702775\\\/21\\\/D%27Amour_Professional_Headshot_%28002%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/","og_locale":"en_US","og_type":"article","og_title":"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Pharma Trend","og_description":"Pioneering cell therapy leader will direct Stemson\u2019s efforts to develop the first iPSC-derived cell therapy to treat hair loss SAN DIEGO–(BUSINESS WIRE)–#stemson—Stemson Therapeutics, a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Kevin D\u2019Amour, a veteran cell therapy development expert, has joined Stemson as Chief Scientific ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-01T17:03:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230201005196\/en\/1702775\/21\/D%27Amour_Professional_Headshot_%28002%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer","datePublished":"2023-02-01T17:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/"},"wordCount":526,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005196\/en\/1702775\/21\/D%27Amour_Professional_Headshot_%28002%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/","url":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/","name":"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005196\/en\/1702775\/21\/D%27Amour_Professional_Headshot_%28002%29.jpg","datePublished":"2023-02-01T17:03:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230201005196\/en\/1702775\/21\/D%27Amour_Professional_Headshot_%28002%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230201005196\/en\/1702775\/21\/D%27Amour_Professional_Headshot_%28002%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kevin-damour-phd-joins-stemson-therapeutics-as-chief-scientific-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kevin D\u2019Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53538"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53538\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}